|Onxeo SA -- Germany Stock|| |
EUR 1.65 0.00 0.00%
Member of the Board - Permanent Representative of Financiere de la Montagne
Dr. Nicolas Trebouta has served as Member of the Board Permanent Representative of Financiere de la Montagne at Bioalliance Pharma SA as of June 29, 2011. Since 2004, he was via his company Financiere de la Montagne, investing in biotechnology companies, directly or through funds. He cofounded Chevrillon et Associe in 2000 and through this structure achieved several LBO such as Picard, CPI or Alingia . He was a Medical Doctor and shareholder of BioAlliance Pharma SA since 2008. Dr. Trebouta also serves as Manager of SARL Financiere de la Montagne, SCI Fleurus Immobilier and SCI du Trillon Chairman of SAS Dragon 8, and Director of GIE IO, among others.
Executive Since 2011
The company has return on total asset (ROA)
of (11.88) %
which means that it has lost $11.88 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (24.16) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 155 K in total debt with debt to equity ratio (D/E) of 0.1 which may suggest the company is not taking enough advantage from borrowing. Onxeo SA has Current Ratio of 3.4 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Onxeo SA (C4X) is traded on Frankfurt Stock Exchange in Germany. and employs 22 people.